Loading...
XNAS
ATRA
Market cap79mUSD
Jul 29, Last price  
11.73USD
Name

Atara Biotherapeutics Inc

Chart & Performance

D1W1MN
P/E
—
P/S
0.61
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-18.26%
Rev. gr., 5y
%
Revenues
129m
+1,404.02%
00000000020,340,00063,573,0008,573,000128,940,000
Net income
-85m
L-69.07%
-123,300,000-87,730,000-280,060,000-572,210,000-790,490,000-1,194,910,000-2,306,990,000-2,909,760,000-3,066,200,000-3,401,410,000-2,283,020,000-276,126,000-85,403,000
CFO
-69m
L-64.39%
-2,475,000-5,966,000-16,628,000-37,156,000-60,025,000-87,502,000-179,772,000-235,626,000-180,759,000-220,522,000-270,430,000-192,977,000-68,717,000
Earnings
Aug 11, 2025

Profile

Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
URL
https://www.atarabio.com/
IPO date
Oct 16, 2014
Employees
317
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
128,940
1,404.02%
8,573
-86.51%
63,573
212.55%
Cost of revenue
212,378
283,468
358,654
Unusual Expense (Income)
NOPBT
(83,438)
(274,895)
(295,081)
NOPBT Margin
Operating Taxes
(12)
15
12
Tax Rate
NOPAT
(83,426)
(274,910)
(295,093)
Net income
(85,403)
-69.07%
(276,126)
-87.91%
(2,283,020)
-32.88%
Dividends
Dividend yield
Proceeds from repurchase of equity
59,951
2,136
23,189
BB yield
Debt
Debt current
12,179
13,640
Long-term debt
59,828
91,386
116,128
Deferred revenue
37,562
77,000
Other long-term liabilities
41,893
39,254
35,800
Net debt
17,332
51,840
(113,051)
Cash flow
Cash from operating activities
(68,717)
(192,977)
(270,430)
CAPEX
(246)
(1,223)
(4,193)
Cash from investing activities
8,624
123,866
202,956
Cash from financing activities
59,282
2,010
53,084
FCF
(24,234)
(231,201)
(289,476)
Balance
Cash
42,496
51,725
242,819
Long term investments
Excess cash
36,049
51,296
239,640
Stockholders' equity
(2,054,544)
(1,969,343)
(1,695,081)
Invested Capital
2,029,068
2,004,800
2,006,225
ROIC
ROCE
327.52%
EV
Common stock shares outstanding
7,488
4,236
40,796
Price
Market cap
EV
EBITDA
(78,627)
(270,066)
(289,428)
EV/EBITDA
Interest
4,615
5,285
1,986
Interest/NOPBT